References
Corbin ZA, Nguyen-Lin A, Li S, Rahbar Z, Tavallaee M, Vogel H, Salva KA, Wood GS, Kim YH, Nagpal S (2017) Characterization of the peripheral neuropathy associated with brentuximab vedotin treatment of Mycosis Fungoides and Sézary Syndrome. J Neurooncol 132:439–446. https://doi.org/10.1007/s11060-017-2389-9
Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, Forero-Torres A (2010) Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 363:1812–1821. https://doi.org/10.1056/NEJMoa1002965
Lewis DJ, Talpur R, Huen AO, Tetzlaff MT, Duvic M (2017) Brentuximab vedotin for patients with refractory lymphomatoid papulosis: an analysis of phase 2 results. JAMA Dermatol 153:1302–1306. https://doi.org/10.1001/jamadermatol.2017.3593
Prince HM, Kim YH, Horwitz SM et al (2017) Brentuximab vedotin or physician’s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet 390:555–566. https://doi.org/10.1016/S0140-6736(17)31266-7
Mariotto S, Ferrari S, Sorio M, Benedetti F, Tridente G, Cavallaro T, Gajofatto A, Monaco S (2015) Brentuximab vedotin: axonal microtubule’s Apollyon. Blood Cancer J 5:e343. https://doi.org/10.1038/bcj.2015.7
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors have nothing to disclose.
Rights and permissions
About this article
Cite this article
Mariotto, S., Ferrari, S. & Monaco, S. Brentuximab vedotin-induced peripheral neuropathy: looking at microtubules. J Neurooncol 137, 665–666 (2018). https://doi.org/10.1007/s11060-018-2743-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11060-018-2743-6